Personalis, Inc. (PSNL)
| Market Cap | 998.92M |
| Revenue (ttm) | 80.37M |
| Net Income (ttm) | -44.55M |
| Shares Out | 42.27M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $22.75 |
| Previous Close | $21.52 |
| Change ($) | 1.23 |
| Change (%) | 5.72% |
| Day's Open | 22.07 |
| Day's Range | 21.72 - 23.75 |
| Day's Volume | 583,032 |
| 52-Week Range | 9.69 - 53.46 |
Personalis (PSNL) delivered earnings and revenue surprises of 21.62% and 2.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the first quarter ended Mar...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 2021 Bank of America Healthca...
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its first quarter 2021 financial results after the market ...
MENLO PARK, Calif.--(BUSINESS WIRE)-- #AACR21--Personalis Presents Data at AACR Annual Meeting 2021 Showcasing the Personalis ImmunoID NeXT Platform
Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MENLO PARK, Calif.--(BUSINESS WIRE)-- #immunooncology--Personalis Announces Collaboration with MapKure to Use Personalis' NeXT Platform for Clinical Trials and Companion Diagnostic Development
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Changes to its Board of Directors
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the fourth quarter and full...
MENLO PARK, Calif.--(BUSINESS WIRE)--Second paragraph, first sentence of release dated February 11, 2021, should read: Interested parties may access the live call via telephone by dialing (866) 220-8061...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the following upcoming investor c...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its fourth quarter 2020 financial results after the market...
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG Virtual MedTech, Digital...
The company announced the pricing of a public offering of common stock.
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced the pricing of its previously announced underwri...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that it has commenced an underwritten public off...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the fourth quar...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that management will present at the 23rd Annual Needham Virtual Growth Con...
MENLO PARK, Calif.--(BUSINESS WIRE)-- #AACR20--Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program
MENLO PARK, Calif.--(BUSINESS WIRE)-- #EACR--Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event
Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.
MENLO PARK, Calif.--(BUSINESS WIRE)-- #AMP2020--Personalis® to Present at the AMP Annual Meeting 2020
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
Personalis' (PSNL) CEO John West on Q3 2020 Results - Earnings Call Transcript
Personalis (PSNL) delivered earnings and revenue surprises of 10.00% and 2.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the third quarter ended Sep...
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investo...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis to Participate in Immuno Series US Virtual Meeting
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc. to Present at IO Combinations 360˚
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis to Participate in Digital World CB & CDx Meeting
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Receives Contract Extension and New Task Order from the VA’s Million Veteran Program – Total Awarded to Date Now $175M
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Strengthens Commercial Team with the Appointment of New Head of Population Genomics
Personalis: Deep Genomics Leader At A Good Price
Personalis (PSNL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
The company, which leans on one customer for 76% of revenue, desperately needs to diversify its customer base.
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis to Participate at the Needham Virtual Cancer Diagnostics 1x1 Conference
The genomics company announced a public offering of common stock.
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Pricing of Public Offering of Common Stock
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis Announces Launch of Public Offering of Common Stock
Personalis, Inc. (PSNL) CEO John West on Q2 2020 Results - Earnings Call Transcript
Personalis (PSNL) delivered earnings and revenue surprises of 14.71% and 14.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis Reports Second Quarter 2020 Financial Results
Personalis, Inc. Launches NeXT Liquid Biopsy™, A High-Performance, Exome-Wide Liquid Biopsy Platform
MENLO PARK, Calif.--(BUSINESS WIRE)-- #PrecisionOncology--Personalis, Inc.
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has par... [Read more...]
| Industry Diagnostics & Research | IPO Date Jun 20, 2019 |
| CEO John West | Employees 234 |
| Stock Exchange NASDAQ | Ticker Symbol PSNL |
Financial Performance
In 2020, Personalis's revenue was $78.65 million, an increase of 20.61% compared to the previous year's $65.21 million. Losses were -$41.28 million, 64.6% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for Personalis stock is "Buy." The 12-month stock price forecast is 37.00, which is an increase of 62.64% from the latest price.